

Korea's IVI inks MoU with Karolinska Institutet to strengthen existing cooperation in vaccine research and education

September 7, 2026 | News

For exploring new approaches to HPV vaccine delivery



Building on an established relationship between the two institutions, South Korea-based International Vaccine Institute (IVI) and Karolinska Institutet (KI) have signed a Memorandum of Understanding (MoU) to expand opportunities for academic and scientific exchange within vaccine research.

The agreement provides a framework for further cooperation, including student and academic exchanges, joint scientific activities, as well as training and capacity-building initiatives.

The partnership between the two institutions dates back to the establishment of IVI's Europe Regional Office in 2022 at the Karolinska Institutet campus in Solna, Stockholm, with support from the Government of Sweden.

IVI and KI are jointly involved in several vaccine research projects, including the Global Burden Estimation of Human Papillomavirus (GLOBE-HPV) study, a multi-country initiative generating data on HPV prevalence among girls and women in low- and middle-income countries across South Asia and sub-Saharan Africa.

HPV causes nearly all cases of cervical cancer, the fourth most common cancer among women globally and the project also examines knowledge, attitudes, gender-related factors, and other barriers affecting HPV vaccination, screening, and treatment.

The partnership is also exploring new approaches to HPV vaccine delivery, including innovative strategies to expand access to vaccination through existing childhood immunization systems.